Detalles de la búsqueda
1.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37506339
2.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38031761
3.
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Eur J Haematol
; 109(6): 755-764, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36063368
4.
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Ann Hematol
; 100(7): 1769-1778, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33885924
5.
Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.
Biol Blood Marrow Transplant
; 26(2): 358-366, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655119
6.
Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
Biol Blood Marrow Transplant
; 26(12): 2237-2244, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32717433
7.
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Br J Haematol
; 191(1): 52-61, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32510599
8.
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Biol Blood Marrow Transplant
; 25(9): 1825-1831, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31152794
9.
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant
; 25(9): 1703-1712, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31054983
10.
Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Haematologica
; 109(5): 1608-1613, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38205539
11.
PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation.
Ann Hematol
; 97(11): 2217-2224, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019128
12.
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Eur J Haematol
; 101(3): 332-339, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846964
13.
Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches.
Biol Blood Marrow Transplant
; 23(12): 2042-2047, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28827064
14.
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Biol Blood Marrow Transplant
; 22(3): 584-8, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26631751
15.
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Br J Haematol
; 174(6): 859-67, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27185197
16.
The implication of 'unknown significance' variants in next-generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene.
Br J Haematol
; 189(4): e182-e184, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32266710
17.
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Haematologica
; 99(10): 1632-7, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24997153
18.
Plasma from patients undergoing allogeneic hematopoietic stem cell transplantation promotes NETOSIS in vitro and correlates with inflammatory parameters and clinical severity.
Front Immunol
; 15: 1353106, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38550584
19.
Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party.
EClinicalMedicine
; 67: 102393, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38152413
20.
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Br J Haematol
; 162(4): 474-82, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23772672